“Stem cell hair treatment” is a broad label, and medical opinion cannot be reduced to a simple yes or no. Some doctors are incorporating stem cell extracts into treatment protocols, particularly alongside platelet-rich plasma (PRP) or microneedling. However, the strength of evidence varies according to the type of hair loss, the product used and the way it is administered.
Dr Daniel Sister, a London-based aesthetic doctor and hormone specialist, has reviewed the published literature on growth factors, PRP and stem cell-based approaches. His conclusion is that stem cell extracts have a logical place in combination treatments for hair loss.
Understanding the distinction requires a closer look at what these treatments contain and what the supporting research has actually found.
Hair loss is not a single condition
Some daily shedding is normal. Fewer than 100 hairs may be lost each day and, under ordinary circumstances, they are replaced by new growth. With age, however, hair can become finer and the growth cycle may become less effective at replacing what is shed.
Stress, illness, hormonal changes, medication or over-styling can also be linked to hair loss. A treatment that has been tested on one type of hair loss may not work for another. The cause is what counts.
Two conditions discussed in Dr Sister’s review are alopecia areata and androgenetic alopecia. Alopecia areata is an autoimmune condition characterised by clearly defined areas of hair loss. It can progress to the complete loss of scalp hair or, in severe cases, hair across the body.
Androgenetic alopecia, commonly called male or female pattern hair loss, is chronic and progressive. Hair follicles gradually become smaller, converting thicker terminal hairs into finer vellus hairs and reducing overall scalp density. It affects up to 80% of Caucasian men and 40% of women, with frequency increasing with age.
Why growth factors attract medical interest
A hair follicle is a living production unit beneath the skin. At its base sits the dermal papilla, which receives nutrients through the bloodstream and plays an important role in maintaining hair growth.
Hair follicle has 3 main phases: anagen or the active growth phase, catagen the transitional phase and telogen the resting phase. If dermal papilla cells are not adequately stimulated, the formation of the hair fiber and the supporting root sheaths can be disrupted.
That’s why growth factors have become relevant to hair loss research. Growth factors have been implicated in the processes of dermal papilla cells, follicular epithelial cells, blood vessels and the hair-growth cycle. For example, vascular endothelial growth factor has been found as a mediator of follicle growth and cycling. Epidermal growth factor is associated with anagen phase while insulin-like growth factor 1 is associated with migration, survival and proliferation of hair-follicle cells.
What PRP research contributes to the discussion
Much of the clinical evidence reviewed by Dr Sister concerns PRP. The treatment uses a concentration of platelets derived from the patient’s own blood. Those platelets release growth factors involved in healing and tissue regeneration.
A systematic review by Pietro Gentile and colleagues examined PRP for androgenetic alopecia in comparison with minoxidil, finasteride and adult stem cell-based therapy. Of 163 articles initially identified, 12 clinical trials met the criteria for analysis. Eighty-four percent reported a positive effect from PRP, including 50% that showed statistically significant improvement through objective measurements. Another 34% reported improvements in hair density and thickness, while 17% found PRP ineffective.
A meta-analysis covering seven studies and 194 patients concluded that local PRP injections might be associated with a higher number of hairs in treated areas, with minimal morbidity. A randomised trial involving 40 people with moderate androgenetic alopecia described subdermal PRP injections as efficacious and tolerable, with potentially greater benefits when treatments were initially administered monthly.
A placebo-controlled study of 30 women also found statistically significant differences in hair density and thickness between PRP-treated and placebo areas. These findings help explain why some practitioners regard growth-factor-based interventions as useful tools. They do not guarantee the same result for every patient.
Where stem cell extracts fit
The term “stem cell treatment” can suggest that living stem cells are being placed into the scalp, but the protocol described by Dr Sister uses a stem cell extract alongside the patient’s plasma. In his approach, PRP and platelet-poor plasma are combined with 2 ml of Calecim Professional’s Advanced Hair System, then administered superficially beneath the scalp and massaged over the treatment area.
He also cites research in which microneedling was used as a method of PRP administration. In a study involving 126 patients with androgenetic alopecia, PRP-treated participants recorded statistically significant improvements in hair density and diameter compared with the control group. The improvements were greater when microneedling was used.
Laboratory findings cited for the Calecim formula offer further context. According to Dr Li Chun Xiang and Dr Yin Hui of Singapore Polytechnic’s Department of Technology, Innovation and Enterprise, dermal papilla cells showed 24% positive growth when exposed to the product at its optimum concentration. The source describes this as comparable to cell growth observed when hair-follicle cells were exposed to minoxidil. It also reports that tumour necrosis factor-alpha, an inflammatory cytokine, was reduced by up to 30 times when exposed to the formula.
Laboratory cell responses are not the same as confirmed clinical outcomes in every person. The distinction matters when assessing promotional claims.
So, do doctors recommend these treatments?
Yes. Dr Sister recommends combining PRP with a stem cell extract and presents published research to support the rationale for that approach. The literature he reviewed also provides evidence for PRP in androgenetic alopecia.
A more accurate conclusion, therefore, is that many doctors recommend specific growth-factor and stem cell extract protocols for selected patients.
Anyone considering such an option should first establish the type and likely cause of their hair loss, then ask exactly what the proposed treatment contains, how it will be administered and which evidence relates to that particular protocol. In an area filled with expansive claims, specificity is one of the best signs of a medically grounded recommendation.
